| drug name | Drug A - Database Configuration 1 |
| classification | Anti-hypertensive, ACE inhibitor |
| pharmacokinetics | Rapidly absorbed, peak plasma levels within 1 hour. Metabolized in the liver, primarily excreted in urine. Renal function significantly affects clearance. Age and kidney function influence dosage and half-life. |
| suggested dosage | 5mg orally once daily, titrated as needed. Adjust based on blood pressure readings and patient response. Maximum daily dose 40mg. |
| indications | Management of essential hypertension. May be used in diabetic nephropathy. |
| safety in pregnancy | Category C. Potential risks to the fetus. Discontinue if pregnancy is suspected or confirmed. Use only when potential benefits outweigh risks. Consult with physician. |
| safety in breastfeeding | Potential excretion into breast milk. Monitor for adverse effects in nursing infants. Consider alternative therapies if possible. Consult with physician. |
| side effects | | 1 | Dizziness | | 2 | Headache | | 3 | Fatigue | | 4 | Cough | | 5 | Hypotension (low blood pressure) | | 6 | Renal impairment (rare) | | 7 | Hyperkalemia (high potassium) - risk elevated in patients with kidney problems |
|
| alternatives | | 1 | | | 2 | | drug name | Drug C | | class | Calcium Channel Blocker |
| | 3 | | drug name | Drug D | | class | Thiazide Diuretic |
|
|
| contraindications | | 1 | Known hypersensitivity to ACE inhibitors | | 2 | History of angioedema (swelling) | | 3 | Bilateral renal artery stenosis | | 4 | Severe renal impairment |
|
| interactions | | 1 | | drug interaction | Lithium, potassium-sparing diuretics, potassium supplements, NSAIDs - potentiate risk of hyperkalemia. |
| | 2 | | drug interaction | Diuretics - may increase risk of hypotension. |
| | 3 | | drug interaction | Others - consult prescribing information. |
|
|
| warnings and precautions | | 1 | Monitor blood pressure closely, especially during initial therapy and dose adjustments. | | 2 | Monitor renal function, particularly in patients with pre-existing renal disease. | | 3 | Monitor serum potassium levels, especially in patients with renal impairment. | | 4 | May cause dizziness; caution advised while operating machinery or driving. |
|
| additional informations | Database Configuration 1 provides detailed pharmacokinetic data, specifically for a 70kg male patient aged 25. Dosage adjustments based on renal function were considered. |
| patient profile | |
